Moisés Óscar Fiesco-Roa

Dr. Moisés Óscar Fiesco-Roa

Laboratorio Citogenética, Instituto Nacional de Pediatría, México
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2024 in Research Square
Verified
Preprint
Open access
PDF file
THTzung-Chien Hsieh
Tzung-Chien Hsieh
HLHellen Lesmann
Hellen Lesmann
AHAlexander Hustinx
Alexander Hustinx
SMShahida Moosa
Shahida Moosa
EMElaine Marchi
Elaine Marchi
EOEric Olinger
Eric Olinger
The most important factor that complicates the work of dysmorphologists is the significant phenotypic variability of the human face. Next-Generation Phenotyping (NGP) tools that assist clinicians with recognizing characteristic syndromic patterns are particularly challenged when confronted with patients from populations different from their training data. To that end, we systematically analyzed the impact of genetic ancestry on facial dysmorphism. For that purpose, we established the GestaltMatcher Database (GMDB) as a reference dataset for medical images of patients with rare genetic disorders from around the world. We collected 10,980 frontal facial images – more than a quarter previously unpublished - from 8,346 patients, representing 581 rare disorders. Although the predominant ancestry is still European (67%), data from underrepresented populations have been increased considerably via global collaborations (19% Asian and 7% African). This includes previously unpublished reports for more than 40% of the African patients. The NGP analysis on this diverse dataset revealed characteristic performance differences depending on the composition of training and test sets corresponding to genetic relatedness. For clinical use of NGP, incorporating non-European patients resulted in a profound enhancement of GestaltMatcher performance. The top-5 accuracy rate increased by +11.29%. Importantly, this improvement in delineating the correct disorder from a facial portrait was achieved without decreasing the performance on European patients. By design, GMDB complies with the FAIR principles by rendering the curated medical data findable, accessible, interoperable, and reusable. This means GMDB can also serve as data for training and benchmarking. In summary, our study on facial dysmorphism on a global sample revealed a considerable cross ancestral phenotypic variability confounding NGP that should be counteracted by international efforts for increasing data diversity. GMDB will serve as a vital reference database for clinicians and a transparent training set for advancing NGP technology.

Verified
Journal Article
Open access
PDF file
PRPedro V. Reyes-Jiménez
Pedro V. Reyes-Jiménez
BTBenilde Garcia de Teresa
Benilde Garcia de Teresa
UJUlises E Juárez-Figueroa
Ulises E Juárez-Figueroa
Fernando Perez VillatoroFernando Perez Villatoro
Fernando Perez Villatoro
Moisés Óscar Fiesco-RoaMoisés Óscar Fiesco-Roa
Moisés Óscar Fiesco-Roa
Sara FriasSara Frias
Sara Frias
Fanconi anemia (FA) is a rare genetic disorder caused by pathogenic variants (PV) in at least 22 genes, which cooperate in the Fanconi anemia/Breast Cancer (FA/BRCA) pathway to maintain genome stability. PV in FANCA, FANCC, and FANCG account for most cases (~90%). This study evaluated the chromosomal, molecular, and physical phenotypic findings of a novel founder FANCG PV, identified in three patients with FA from the Mixe community of Oaxaca, Mexico. All patients presented chromosomal instability and a homozygous PV, FANCG: c.511-3_511-2delCA, identified by next-generation sequencing analysis. Bioinformatic predictions suggest that this deletion disrupts a splice acceptor site promoting the exon 5 skipping. Analysis of Cytoscan 750 K arrays for haplotyping and global ancestry supported the Mexican origin and founder effect of the variant, reaffirming the high frequency of founder PV in FANCG. The degree of bone marrow failure and physical findings (described through the acronyms VACTERL-H and PHENOS) were used to depict the phenotype of the patients. Despite having a similar frequency of chromosomal aberrations and genetic constitution, the phenotype showed a wide spectrum of severity. The identification of a founder PV could help for a systematic and accurate genetic screening of patients with FA suspicion in this population.

28 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SSSILVIA SANCHEZ
SILVIA SANCHEZ
BTBenilde Garcia de Teresa
Benilde Garcia de Teresa
MMMarco A. Mejía-Barrera
Marco A. Mejía-Barrera
PRPedro V. Reyes-Jiménez
Pedro V. Reyes-Jiménez
AMAntonio De Jesús Paz Martínez
Antonio De Jesús Paz Martínez
Sara FriasSara Frias
Sara Frias
Background/objectives: Fanconi anemia (FA) is an inherited bone marrow failure syndrome characterized by chromosome instability and predisposition to develop myelodysplastic neoplasm (MDS) and acute myeloid leukemia (AML). Clonal chromosome aberrations (CCAs) in chromosomes 1, 3, and 7 frequently appear in the bone marrow (BM) of patients with FA and are associated with MDS/AML progression. Given the underlying DNA repair defect that characterizes FA, non-clonal chromosomal abnormalities (NCCAs) are expected to be common events in the FA BM; in this study, we investigated the presence and significance of NCCA and CCA in the bone marrow (BM) of patients with FA. Methods: Here, we transversally examined the BM karyotypes of 43 non-transplanted patients with FA, 41 with non-clinically detectable hematologic neoplasia and two with diagnosed MDS. We searched for the presence of NCCAs, complex karyotypes (CKs), and CCAs as well as their association with the natural history of the disease, including age, degree of BM failure, and neoplastic transformation. Results: NCCAs were observed in the metaphase spreads of 41/43 FA patients; CKs were observed in 25/43 patients; CCAs were found in 15/43 patients; CCAs involving chromosomes 1, 3 and/or 7 were found in four patients; and other autosomes were found in the remaining 11 patients. Overall, we observed a baseline large karyotypic heterogeneity in the BM of FA patients, demonstrated by the ubiquitous presence of NCCA; such karyotypic heterogeneity precedes the eventual emergence of CKs and selection of cells carrying fitness-improving CCAs. Finally, CCAs involving chromosomes 1, 3 and 7, well-known drivers of hematological malignancy in FA, become established. Overall, we observed that the frequency of NCCAs and CCAs increased with age, even though a significant correlation was not found. Conclusions: These observations fit the model of evolution towards cancer that comprises a first phase of macroevolution represented by NCCAs and karyotypic heterogeneity, followed by the establishment of clones with CCAs, leading to microevolution and cancer. NCCAs are the most frequent chromosomal alterations in the bone marrow of patients with AF and constitute a genome with extensive karyotypic heterogeneity that evolves into clones with more complex genomes and can eventually progress to cancer.

25 April 2022 in Acta Pediátrica de México
Verified
Journal Article
Open access
PDF file
Moisés Óscar Fiesco-RoaMoisés Óscar Fiesco-Roa
Moisés Óscar Fiesco-Roa
PGPaulina G Gómez-Moreno
Paulina G Gómez-Moreno
RERubí M Espinosa-Curiel
Rubí M Espinosa-Curiel
ARAlfredo Rodríguez
Alfredo Rodríguez
Sara FriasSara Frias
Sara Frias
La anemia de Fanconi es un síndrome de inestabilidad cromosómica que cursa con falla medular, alteraciones dismorfológicas y predisposición a cáncer. Las manifestaciones de esta enfermedad incluyen anomalías del desarrollo que son parte de los acrónimos VACTERL-H y PHENOS. Estas alteraciones pueden detectarse a edades tempranas, incluso antes del inicio de las manifestaciones hemato-oncológicas. Aquí describimos cómo la búsqueda y evaluación de estas manifestaciones puede conducir a un diagnóstico temprano de la anemia de Fanconi. Fanconi anemia is a chromosome instability syndrome associated with bone marrow failure, physical abnormalities, and cancer predisposition. The Fanconi anemia phenotype includes several morphological anomalies that are part of the VACTERL-H and PHENOS acronyms. These physical alterations can be detected at an early age, even before the onset of hemato-oncological manifestations. Here we describe how to look for and evaluate these manifestations, leading to an early diagnosis of Fanconi anemia.

17 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
SSSILVIA SANCHEZ
SILVIA SANCHEZ
BTBenilde Garcia de Teresa
Benilde Garcia de Teresa
MMMarco A. Mejía-Barrera
Marco A. Mejía-Barrera
PRPedro V. Reyes-Jiménez
Pedro V. Reyes-Jiménez
AMAntonio De Jesús Paz Martínez
Antonio De Jesús Paz Martínez
Sara FriasSara Frias
Sara Frias
Fanconi anemia (FA) is an inherited bone marrow failure syndrome characterized by chromosome instability and predisposition to develop myelodysplastic neoplasm (MDS) and acute myeloid leukemia (AML). Clonal chromosome aberrations (CCA) in chro-mosomes 1, 3, and 7 frequently appear in the bone marrow (BM) of patients with FA and associate to MDS/AML progression. Given the underlying DNA repair defect that characterizes FA, non-clonal chromosomal abnormalities (NCCA) are expected to be common events in the FA BM, however little is known about its presence and significance. Here, we transversally examined the BM karyotypes of 43 non-transplanted patients with FA, 41 with non-clinically detectable hematologic neoplasia and two with diagnosed MDS. We searched for the presence of NCCAs, complex karyotypes (CKs) and CCA, and their association with the natural history of the disease, including age, degree of BM failure, and neoplastic transformation. NCCAs were observed in the metaphase spreads of 41/43 FA patients; CKs were observed in 25/43 patients, whereas CCAs were found in 15/43 patients, CCA involving chromosomes 1, 3 and/or 7 in four patients, and other autosomes in the remaining 11 patients. Overall, we observed a baseline large karyotypic heterogeneity in the BM of FA patients, demonstrated by the ubiquitous presence of NCCA; such karyotypic heterogeneity preceding the eventual emergence of CKs and selection of cells carrying fitness-improving CCAs. Finally, CCAs involving chromosomes 1, 3 and 7, well-known drivers of hematological malignancy in FA, become established. Overall, we observed that the frequency of NCCA and CCA increased with age, even though a significant correlation was not found. Preleukemic BM of patients with FA displays a baseline large karyotypic heterogeneity, evidenced by the ubiquitous presence of NCCA; such karyotypic heterogeneity preceding the eventual emergence of CKs and selection of cells carrying fitness-improving CCAs. Finally, CCAs involving chromosomes 1, 3 and 7, well-known drivers of hematological malignancy in FA, become established. These observations fit the model of evolution towards cancer that comprises a first phase of macroevolution represented by NCCA and karyotypic heterogeneity, followed by the establishment of clones with CCA, leading to microevolution and cancer.

29 December 2021 in Preprints.org
Verified
Preprint
Open access
PDF file
PRPedro V. Reyes-Jiménez
Pedro V. Reyes-Jiménez
BTBenilde Garcia de Teresa
Benilde Garcia de Teresa
UJUlises E Juárez-Figueroa
Ulises E Juárez-Figueroa
Fernando Perez VillatoroFernando Perez Villatoro
Fernando Perez Villatoro
Moisés Óscar Fiesco-RoaMoisés Óscar Fiesco-Roa
Moisés Óscar Fiesco-Roa
Sara FriasSara Frias
Sara Frias
Fanconi anemia (FA) is a rare genetic disorder caused by pathogenic variants (PV) in at least 22 genes, which cooperate in the FA/BRCA pathway to maintain genome stability. PV in FANCA, FANCC, and FANCG account for most cases (~90%). This study evaluated the chromosomal, molecular, and phenotypic findings of a novel founder FANCG PV, identified in three patients with FA from the Mixe community of Oaxaca, Mexico. All patients presented chromosomal instability and a homozygous PV, FANCG: c.511-3_511-2delCA, identified by next-generation sequencing analysis. Bioinformatics predictions suggest that this deletion disrupts a splice acceptor site promoting the exon 5 skipping. Analysis of Cytoscan 750K arrays for haplotyping and global ancestry supported the Mexican origin and founder effect of the variant, reaffirming the high frequency of founder PV in FANCG. The degree of bone marrow failure and physical findings (described through the acronyms VACTERL-H and PHENOS) were used to depict the phenotype of the patients. Despite having a similar frequency of chromosomal aberrations and genetic constitution, the phenotype showed a wide spectrum of severity. The identification of a founder PV could help for a systematic and accurate genetic screening of patients with FA suspicion in this population.